启迪药业:2024年报净利润-1.25亿 同比下降600%

Financial Performance - The company reported a basic earnings per share of -0.5240 yuan for 2024, a decrease of 597.15% compared to 0.1054 yuan in 2023 [1] - The net profit for 2024 was -1.25 billion yuan, representing a 600% decline from 0.25 billion yuan in 2023 [1] - The operating revenue decreased by 15.31% to 3.43 billion yuan in 2024 from 4.05 billion yuan in 2023 [1] - The return on equity was -18.98% in 2024, a significant drop from 3.55% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 12,256.52 million shares, accounting for 51.2% of the circulating shares, with an increase of 462.31 million shares compared to the previous period [1] - The largest shareholder, Qidi Technology Service Co., Ltd., holds 5,860.70 million shares, representing 24.48% of the total share capital [2] - New entrants among the top shareholders include Hu Libo, Wei Xiaoou, and Fan Zukang, while Wang Qi and others have exited the top ten shareholders list [2] Dividend Distribution - The company has announced no distribution or capital increase for the current period [3]